Banner Health, Sera Prognostics Team Up to Provide PreTRM Test to Covered Pregnant Members

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Banner Health today announced that Sera’s PreTRM® Test will be available to Banner – University Family Care/ AHCCCS Complete Care (B – UFC/ACC) members.

The PreTRM Test is the only broadly clinically validated, commercially available blood test that provides an early, individual risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies.

B – UFC/ACC is a Medicaid plan offered by Banner – University Health Plans, which is based in Tucson, AZ, and serves more than 300,000 members in ten Arizona counties.

“We are very pleased to work with Banner Health, which shares our commitment to reducing the adverse consequences of preterm birth. This organization is respected nationwide as an innovative leader in new healthcare models designed to optimize its members’ health while reducing the costs of care,” said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. “Preterm birth is associated with health complications that can affect babies at birth and also throughout the rest of their lives. Prematurity impacts not only mothers and the babies themselves but also their families, healthcare providers, payers, and communities. We developed the PreTRM® Test to help pregnant women and their physicians understand and take actions to mitigate elevated risks of premature birth, with the important goal of improving the health of mothers and babies and, in so doing, reducing healthcare system costs and burden.”

A rigorous health economic analysis published in ClinicoEconomics and Outcomes Research (https://www.dovepress.com/cost-effectiveness-of-a-proteomic-test-for-preterm-birth-prediction-peer-reviewed-fulltext-article-CEOR) in September 2021 shows that application of the PreTRM® strategy, consisting of testing and proactive, evidence-based interventions, improves neonatal outcomes and reduces immediate and long-term treatment costs associated with premature birth when compared to routine care.

“Value, not volume, is Banner’s driving factor, and our providers are rewarded for high-quality results and providing the latest in evidence-based preventive care,” said Robert Krauss, MD, Medical Director, Banner – University Health Plans. “A growing body of evidence supports the potential for the PreTRM® Test to improve fetal-maternal health outcomes and reduce the costs associated with premature birth. Making this cutting-edge predictive test available to our members advances our goal of improving the health of our member populations overall by providing individualized care that helps each member achieve the highest level of wellness. We are excited to integrate the PreTRM® Test into our fetal-maternal care protocols.”

The PreTRM® Test was developed and validated for prediction of spontaneous preterm birth (sPTB) broadly in the U.S. in the Proteomic Assessment of Preterm Risk (PAPR) study. In a subsequent large prospective U.S. study, the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP), the biomarkers were further demonstrated to be predictive of very early preterm birth of any cause, length of neonatal hospital stay, and neonatal morbidity and mortality. Additional new data published in May 2022 showed improved PreTRM® Test predictive performance for women whose due dates are more reliably determined by ultrasound.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution